fda cdrh staff directory

Silver Spring, MD 20993-0002, U.S. Food & Drug Administration FDA Center for Devices and Radiological Health - Wikipedia (b) Each refilling of a prescription shall be entered on the back of the prescription or on another appropriate document or electronic prescription record. The site is secure. (2) Keep a record of the date of receipt of the transmitted prescription, the name of the licensed pharmacist filling the prescription, and dates of filling or refilling of the prescription; Authority: 21 U.S.C. SOP: Management of Review Staff Changes During the Review of a However, pharmacies electronically sharing a real-time, online database may transfer up to the maximum refills permitted by law and the prescriber's authorization. 1306.14 Labeling of substances and filling of prescriptions. Note: If you need help accessing information in different file formats, see The facsimile serves as the original written prescription for purposes of this paragraph (g) and it shall be maintained in accordance with 1304.04(h). 24, 1997]. CDRH Management Directory by Organization | FDA Phone: 301-348-1474, An official website of the United States government, Recalls, Market Withdrawals and Safety Alerts, Office of Science and Engineering Laboratories, Office of Strategic Partnerships and Technology Innovation, Center for Devices and Radiological Health, Office of CommunicationandEducation - Division of Communication Media, CDRH Management Directory by Organization. (3) Retrieval of partially filled Schedule II prescription information is the same as required by 1306.22(b) (4) and (5) for Schedule III and IV prescription refill information. Background CDRH strives. (4) The prescribing practitioner must execute a new and separate prescription for any additional quantities beyond the five-refill, six-month limitation. Such emergency treatment may be carried out for not more than three days and may not be renewed or extended. 1. - Effect to the device by electromagnetic disturbances were tested and evaluated according to the FDA-recognized consensus standard IEC 60601-1-2. Not more than one day's medication may be administered to the person or for the person's use at one time. For specific phone numbers and email addresses for each office, division, and team, see the CDRH Management Directory by Organization. 1306.24 Labeling of substances and filling of prescriptions. The .gov means it's official. A paper prescription for a Schedule II controlled substance may be transmitted by the practitioner or the practitioner's agent to a pharmacy via facsimile equipment, provided that the original manually signed prescription is presented to the pharmacist for review prior to the actual dispensing of the controlled substance, except as noted in paragraph (e), (f), or (g) of this section. Language Assistance Available: Espaol | | Ting Vit | | Tagalog | | | Kreyl Ayisyen | Franais | Polski | Portugus | Italiano | Deutsch | | | English, The information on this page is current as of. Contact: Bobbi Dresser, Program Analyst, (for general information). (c) The requirements of paragraph (a) of this section do not apply when a controlled substance listed in Schedule III, IV, or V is prescribed for administration to an ultimate user who is institutionalized: Provided, That: (1) Not more than a 34-day supply or 100 dosage units, whichever is less, of the controlled substance listed in Schedule III, IV, or V is dispensed at one time; (2) The controlled substance listed in Schedule III, IV, or V is not in the possession of the ultimate user prior to administration; (3) The institution maintains appropriate safeguards and records the proper administration, control, dispensing, and storage of the controlled substance listed in Schedule III, IV, or V; and. Purpose This document describes Standard Operating Procedures (SOP) for CDRH's management of review staff changes during the review of a premarket submission. 24, 1997; 75 FR 16308, Mar. Before sharing sensitive information, make sure you're on a federal government site. In the fall of 2018, the U.S. Food & Drug Administration's (FDA) Center for Medical Devices and Radiological Health (CDRH) announced the largest reorganization in years to initiate the Total Product Life Cycle (TPLC) approach across the institution (read more here).Fast forward to May 1, 2019the date that the CDRH declared that it had fully implemented the new TPLC organizational . For network communications, a set of protocols to be followed by devices claiming conformance to the Standard. 24, 1997, as amended at 68 FR 37411, June 24, 2003]. CBER Key Staff Directory; Contacts in CBER; Information about the Center Director. 1 2. (c) The following information must be retrievable by the prescription number: (1) The name and dosage form of the controlled substance. These modules provide industry with information that is comprehensive, interactive, and easily accessible. To close chapter view, click the X in the upper right-hand corner. Division Director. Source: 36 FR 7799, Apr. (b) Transfers are subject to the following requirements: (1) The transfer must be communicated directly between two licensed pharmacists. The Center for Devices and Radiological Health (CDRH) is the branch of the United States Food and Drug Administration (FDA) responsible for the premarket approval of all medical devices, as well as overseeing the manufacturing, performance and safety of these devices.The CDRH also oversees the radiation safety performance of non-medical devices which emit certain types of electromagnetic . CDRH Management Directory by Organization . Phone: 301-348-1474. Center for Devices and Radiological Health (5) In the event that a pharmacy which employs such a computerized application experiences system down-time, the pharmacy must have an auxiliary procedure which will be used for documentation of refills of Schedule III and IV controlled substance prescription orders. Rules governing the issuance, filling and filing of prescriptions pursuant to section 309 of the Act (21 U.S.C. (b) A prescription for a Schedule II controlled substance written for a patient in a Long Term Care Facility (LTCF) or for a patient with a medical diagnosis documenting a terminal illness may be filled in partial quantities to include individual dosage units. No further quantity may be supplied beyond 72 hours without a new prescription. 16071 Industrial Drive, HFZ-260. 1306.11 Requirement of prescription. 31, 2010]. This draft guidance provides a risk-based framework to guide manufacturers and FDA staff on the human factors information that should be included in a marketing submission to the Center for Devices and Radiological Health to facilitate the efficiency of the FDA review process. (d) All prescriptions for controlled substances listed in Schedules III, IV, and V shall be kept in accordance with 1304.04(h) of this chapter. U.S. Food & Drug Administration Employee Directory. Instructions for Downloading Viewers and Players. (d) A practitioner may sign a paper prescription in the same manner as he would sign a check or legal document (e.g., J.H. Suggested tip before you watch this module: Gather the materials you'll need to prepare Form FDA 3602 or Form FDA 3602A. (a) The pharmacist filling a written or emergency oral prescription for a controlled substance listed in Schedule II shall affix to the package a label showing date of filling, the pharmacy name and address, the serial number of the prescription, the name of the patient, the name of the prescribing practitioner, and directions for use and cautionary statements, if any, contained in such prescription or required by law. Food and Drug Administration Center for Devices and Radiological Health If such an application provides a hard-copy printout of each day's controlled substance prescription order refill data, that printout shall be verified, dated, and signed by the individual pharmacist who refilled such a prescription order. 1306.21 Requirement of prescription. Gaithersburg, MD 20877 Training and Continuing Education, Recalls, Market Withdrawals and Safety Alerts, How to submit a Small Business Certification Request, Unique Device Identification (UDI) System, 510(k) Third Party Review Program (for Third Party Review Organizations), Workshop Page with Presentation in Segments, Workshop Page with Presentation inSegments. The Patient and Caregiver Connection provides patients and caregivers with an opportunity to share their experiences living with a condition or using medical devices with FDA's Center for Devices. Device Advice is CDRH's premier text-based resource for comprehensive regulatory education that explains medical device laws, regulations, guidances, and policies, across the entire product life cycle. Unique Device Identification: Convenience Kits, Final GuidancePresentation Printable Slides Transcript, COVID-19 Transition Policy - (Updated module 04/27/23), COVID-19 Transition Policy for Devices, Final Guidances - Updated 04/27/23Presentation Printable Slides Transcript, Dental Devices Premarket SubmissionsPresentation Printable Slides Transcript, Final Guidance on "General Wellness: Policy for Low-Risk Devices". (2) Ensure that all information required to be on a prescription pursuant to Section 1306.05 of this part is transmitted to the central fill pharmacy (either on the face of the prescription or in the electronic transmission of information); (3) Maintain the original prescription for a period of two years from the date the prescription was filled; (4) Keep a record of receipt of the filled prescription, including the date of receipt, the method of delivery (private, common or contract carrier) and the name of the retail pharmacy employee accepting delivery. For more specific information including emails and phone numbers seethe CDRH Management Directory by Organization. March 2016 Industry Basics Workshop: Unique Device Identification (UDI) Part II, Submitting Information to GUDIDFull PresentationWorkshop PageJanuary 2016 Industry Basics Workshop: Unique Device Identification (UDI) Part IFull PresentationWorkshop Page, November 2015 Industry Basics Workshop: Purchasing Controls and Process ValidationFull PresentationWorkshop Page with Presentation in Segments, November 2014 Industry Basics Workshop: IDE, 510(k), de novo, CAPA, eMDRFullPresentationWorkshop Page with Presentation inSegments. [36 FR 13368, July 21, 1971, as amended at 37 FR 15921, Aug. 8, 1972. Smith, or John H. Smith). If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. (f) As an alternative to the procedures provided by paragraphs (a) through (e) of this section, a computer application may be used for the storage and retrieval of refill information for original paper prescription orders for controlled substances in Schedule III and IV, subject to the following conditions: (1) Any such proposed computerized application must provide online retrieval (via computer monitor or hard-copy printout) of original prescription order information for those prescription orders that are currently authorized for refilling. CDRH Definition: A text definition of the term created by an FDA subject matter expert. 1306.23 Partial filling of prescriptions. Stacey Wilson. Sec. (2) The transferring pharmacist must do the following: (i) Write the word "VOID" on the face of the invalidated prescription; for electronic prescriptions, information that the prescription has been transferred must be added to the prescription record. Unique Device Identification (UDI) System Regulatory OverviewPresentationPrintable SlidesTranscript, 2. (2) The practitioner is in compliance with DEA regulations regarding treatment qualifications, security, records, and unsupervised use of the drugs pursuant to the Act. The site is secure. (b) In accordance with the Act, it is unlawful for any person to knowingly or intentionally fill a prescription for a controlled substance that was issued in a manner that constitutes dispensing by means of the Internet unless such person is a pharmacist who is acting in the usual course of his professional practice and is acting on behalf of a pharmacy whose registration has been modified under sections 1301.13 and 1301.19 of this chapter to authorize it to operate as an online pharmacy. PDF Procedures for Meetings of the Medical Devices Advisory - FDAnews (d) A prescription may be issued by a qualifying practitioner, as defined in section 303(g)(2)G)(iii) of the Act (21 U.S.C. The .gov means its official.Federal government websites often end in .gov or .mil. 31, 2010], Controlled Substances Listed in Schedules III, IV, and V. (a) A pharmacist may dispense directly a controlled substance listed in Schedule III, IV, or V that is a prescription drug as determined under section 503(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Who We Are. (h) When filing refill information for electronic prescriptions, a pharmacy must use an application that meets the requirements of part 1311 of this chapter. Redesignated at 38 FR 26609, Sept. 24, 1973, as amended at 62 FR 13965, Mar. 353(b)) only pursuant to a written prescription signed by the practitioner, except as provided in paragraph (d) of this section. (4) Any such computerized application shall have the capability of producing a printout of any refill data that the user pharmacy is responsible for maintaining under the Act and its implementing regulations. (d) If the pharmacist merely initials and dates the back of the prescription or annotates the electronic prescription record, it shall be deemed that the full face amount of the prescription has been dispensed. This printout of the day's controlled substance prescription order refill data must be provided to each pharmacy using such a computerized application within 72 hours of the date on which the refill was dispensed. (2) Any such proposed computerized application must also provide online retrieval (via computer monitor or hard-copy printout) of the current refill history for Schedule III or IV controlled substance prescription orders (those authorized for refill during the past six months). (v) The name, address, DEA registration number, and prescription number from the pharmacy that originally filled the prescription, if different. 24, 1997; 68 FR 37411, June 24, 2003]. Silver Spring, MD 20993-0002, Food & Drug Administration (b) An individual practitioner may administer or dispense directly a controlled substance listed in Schedule II in the course of his professional practice without a prescription, subject to 1306.07. 2021 and 2020 virtual town hall presentations and transcripts are archived and located in the Specialty Technical Topics sectionas: Coronavirus (COVID-19) Test Development and Validation Virtual Town Hall Series. 1306.25 Transfer between pharmacies of prescription information for Schedules III, IV, and V controlled substances for refill purposes. 821, 823, 829, 829a, 831, 871(b) unless otherwise noted. (e) Where a prescription that has been prepared in accordance with section 1306.12(b) contains instructions from the prescribing practitioner indicating that the prescription shall not be filled until a certain date, no pharmacist may fill the prescription before that date. [62 FR 13965, Mar. PresentationPrintable SlidesTranscript, Digital Health Software Precertification (PreCert) Pilot ProgramPresentationPrintable SlidesTranscript, Hearing Aids and Personal Sound Amplification ProductsPresentationPrintable SlidesTranscript, Overview of the Final Order calling for PMAs for AEDsPresentationPrintable SlidesTranscript, Self Monitoring Blood Glucose Systems for Over-the-Counter Use & Blood Glucose Monitoring Systems for Prescription Point-of-Care UsePresentationPrintable SlidesTranscript, Medical Devices Containing Materials Derived from Animal Sources (Except for In Vitro Diagnostic Devices) Final GuidancePresentation Printable Slides Transcript, Final Guidance on "Use of International Standard ISO 10993-1, Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process"PresentationPrintable SlidesTranscript, Color AdditivesPresentationPrintable SlidesTranscript, Collaborative Communities: Addressing Healthcare Challenges TogetherPresentation Printable Slides Transcript, Custom Device ExemptionPresentationPrintable SlidesTranscript, Technical Considerations for Additive Manufactured Medical DevicesPresentationPrintable SlidesTranscript, Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence/Machine Learning (AI/ML)-Enabled Device Software Functions -NEW 04/21/23Presentation Printable Slides Transcript, Content of Premarket Submissions for Device Software Functions, Draft GuidancePresentation Printable Slides Transcript, Digital Health Software Precertification (Pre-Cert) Pilot ProgramPresentationPrintable SlidesTranscript, Digital HealthPresentationPrintable SlidesTranscript, Design Considerations and Premarket Submission Recommendations for Interoperable Medical Devices Final GuidancePresentationPrintable SlidesTranscript, Clinical Decision Support Software, Final Guidance(Updated 11/3/2022)PresentationPrintable SlidesTranscript, Clinical Decision Support Software: Draft GuidancePresentation Printable Slides Transcript, Changes to Existing Medical Software Policies Resulting from Section 3060 of the 21st Century Cures Act: Final GuidancePresentation Printable Slides Transcript, Content of Premarket Submissions for Management of Cybersecurity in Medical DevicesPresentationPrintable SlidesTranscript, Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions - Draft GuidancePresentation Printable Slides Transcript, Postmarket Management of Cybersecurity in Medical Devices Final GuidancePresentationPrintableSlidesTranscript, PreCertification (Pre-Cert) Pilot UpdatePresentationPrintable SlidesTranscript, Digital Health Center of Excellence Listening Session #1Presentation Printable Slides Transcript, Digital Health Center of Excellence Listening Session #2Presentation Printable Slides Transcript, Applying Human Factors and Usability Engineering to Medical DevicesPresentationPrintable SlidesTranscript, FDA's Home Use Medical Device InitiativePresentationPrintable Slides, Promoting Patient Safety with Home Use DevicesPresentationPrintable Slides, Home Use Medical Devices: New RisksPresentationPrintable Slides, Medical Devices in the Home: Design Considerations and Guidance for IndustryPresentationPrintable SlidesTranscript, Testing and Labeling Medical Devices for Safety in the Magnetic Resonance (MR) EnvironmentPresentation Printable Slides Transcript, Regulatory Advice for Investigators and Sponsors of Neurological Devices and the Path to Initiating Human StudiesPresentationPrintable SlidesTranscript, Regulatory Overview for Developers and Sponsors of Neurological Devices: An Introduction to Premarket ApprovalsPresentationPrintable SlidesTranscript, Regulatory Overview for Developers and Sponsors of Neurological and Physical Medicine Devices: An Introduction to the De Novo PathwayPresentation Printable Slides Transcript, Regulatory Overview for Developers and Sponsors of Neurological Devices: An Introduction to Humanitarian Device Exemptions (HDEs)Presentation Printable Slides Transcript, FDA Innovation Challenge: Devices to Prevent and Treat Opioid Use DisorderPresentation Printable Slides Transcript, Implanted BCI Devices for Patients with Paralysis or Amputation - Non-clinical Testing and Clinical Considerations Final GuidancePresentation Printable Slides Transcript, Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use In Medical Device Evaluation, Final GuidancePresentation Printable Slides Transcript, Patient Engagement in the Design and Conduct of Medical Device Clinical Studies, Final GuidancePresentation Printable Slides Transcript, Enforcement Policy for Personal Protective Equipment (PPE) During COVID-19: Immediately in Effect Guidance - April 6, 2020Presentation Printable Slides Transcript, Respirators for Health Care Personnel Use during COVID-19 Pandemic - June 9, 2020Presentation Printable Slides Transcript, Respirators for Health Care Personnel Use during COVID-19 Pandemic- June 23, 2020Presentation Printable Slides Transcript, Respirators for Health Care Personnel Use during COVID-19 Pandemic - July 7, 2020Presentation Printable Slides Transcript, Respirators for Health Care Personnel Use during COVID-19 Pandemic - July 21, 2020Presentation Transcript, Regulation of Face Masks and Surgical Masks During the COVID-19 Pandemic - August 4, 2020PresentationTranscript, FDA's Surgical Masks Umbrella EUA - August 18, 2020Presentation Transcript, CDC/NIOSH's Surgical N95 Respirator Guidance - September 1, 2020Presentation Printable Slides Transcript, Gowns and Other Apparel for Use by Health Care Personnel in COVID-19 PandemicPresentation Printable Slides Transcript, Respirators and Other PPE for Health Care Personnel UsePresentation Transcript, Protective Barrier Enclosure Emergency Use Authorizations (EUAs)Presentation Printable Slides Transcript, Respirators and Other Personal Protective Equipment (PPE) for Health Care Personnel Use During the COVID-19 PandemicPresentation Printable SlidesTranscript, Gowns- Regulatory ResponsibilitiesPresentationPrintable SlidesTranscript, Respirators and Other Personal Protective Equipment (PPE) for Health Care Personnel Use During the COVID-19 PandemicPresentation Printable Slides Transcfript, Enforcement Policy for Bioburden Reduction Systems Using Dry Heat to Support Single-User Reuse of Certain Filtering Facepiece Respirators during the COVID-19 PandemicPresentation Printable Slides TranscriptTAKE OUR SURVEY - Tell us what you think about the webinar, Respirators and Other Personal Protective Equipment (PPE) for Health Care Personnel Use During the COVID-19 PandemicPresentationPrintable Slides Transcript, Transitioning from the Use of Decontaminated Disposable RespiratorsPresentation Printable Slides Transcript, Respirators and Other Personal Protective Equipment (PPE) for Health Care Personnel Use During the COVID-19 PandemicPrintable Slides, Respirators and Other Personal Protective Equipment (PPE) for Health Care Personnel Use During the COVID-19 PandemicPresentation Printable Slides TranscriptTAKE OUR SURVEY - Tell us what you think about the webinar, Targeted Box and Blocks Test (tBBT)(New 12/13/22)PresentationTranscript, Webinar - Duodenoscope Sampling and CulturingPresentationPrintable SlidesTranscript, Reprocessing Medical Devices in Health Care Settings: Validation Methodsand LabelingPresentationPrintable SlidesTranscript, FDA Innovation Challenges: Identify Sterilization Alternatives and Reduce Ethylene Oxide EmissionsPrintable Slides Transcript, Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile Final GuidancePresentationPrintable SlidesTranscript, How to Get Your Electronic Product on the U.S. MarketPresentation Printable Slides Transcript, Electronic Product Certification and Quality Testing ProgramsPresentation Printable Slides Transcript, Marketing Clearance of Diagnostic Ultrasound Systems and Transducers: Final GuidancePresentationPrintable Slides Transcript, Pediatric Information for X-ray Imaging Device Premarket NotificationsPresentationPrintable SlidesTranscript, Phantom Image Scoring (For MQSA Inspectors)Presentation, eSubmitter Tutorial PresentationseSubmitter Tutorial PresentationsRadiological Health Report Tutorial, 510(k) Third Party Review Program: OverviewPresentation Transcript, X-Ray SystemsPresentation Printable Slides Transcript, 510(k) Third Party Review Program: Final Guidance510(k) Third Party Review Program: Final GuidancePresentation Printable Slides Transcript, Overview of the 510(k) Process: Guide for Third Party ReviewersPresentation Printable Slides Transcript, Deficiency Writing for Third Party ReviewersPresentation Printable Slides Transcript, Deficiency Writing for Third Party Reviewers: ExamplesPresentation Printable Slides Transcript, November 2022 Industry Basics Workshop: Understanding Risk Management with Medical Devices (New12/5/22)Full Presentation Workshop Page, April 2021 Industry Basics Workshop: Consensus Standards and the Accreditation Scheme for Conformity Assessment (ASCA) PilotFull Presentation Workshop Page, November2019 Industry Basics Workshop: 513(g) Requests for Information andCustom DeviceExemptionFull Presentation Workshop Page, November 2018 Industry Basics Workshop: Production and Process Controls; and Documents, Change Control, and RecordsFull Presentation Workshop Page, November 2017 Industry Basics Workshop: Quality System - Nonconforming Product and Complaint FilesFull PresentationWorkshop PageTranscript. CDRH Preferred Term: The CDRH preferred term attached to the concept. (4) The system employed by the pharmacist in filling a prescription is adequate to identify the supplier, the product and the patient, and to set forth the directions for use and cautionary statements, if any, contained in the prescription or required by law. Tips for Viewing Modules CDRH 2022 Annual Report. (b) A prescription issued by an individual practitioner may be communicated to a pharmacist by an employee or agent of the individual practitioner. Office of Communication and Education | FDA Office of Management | FDA 10903 New Hampshire Avenue Assistant Director for Committee Management and Planning. - Usability was documented by referring to IEC 60601-1-6. Such a printout must include name of the prescribing practitioner, name and address of the patient, quantity dispensed on each refill, date of dispensing for each refill, name or identification code of the dispensing pharmacist, and the number of the original prescription order. Sec. Recognized Consensus Standards - Food and Drug Administration FDA CDRH: New Organizational Structure Effective May 1, 2019 301-443-5807. CDRH Learn is our multi-media educational resource, featuring learning modules that address medical device and radiation emitting product laws, regulations, guidances, and policies, across the entire product life cycle. If there is any question whether a patient may be classified as having a terminal illness, the pharmacist must contact the practitioner prior to partially filling the prescription. The pharmacist must notify the nearest office of the Administration if the prescribing individual practitioner fails to deliver a written prescription to him; failure of the pharmacist to do so shall void the authority conferred by this paragraph to dispense without a written prescription of a prescribing individual practitioner.
Girlfriend Feels Overwhelmed And Wants A Break, Articles F